Neurocrine Biosciences, Inc. (NBIX) Financial Statements
Neurocrine Biosciences, Inc. (NBIX) reported trailing twelve-month revenue of $3.4B (up 34.4% year on year) and net income of $705.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $870.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBIXNeurocrine Biosciences, Inc.Follow NBIX — free
—
Price chart with a free account
- Market cap
- 14.5B
- P/E TTM
- 20.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.08 | 0.05 | 0.00 | 0.02 | 0.02 | 0.16 | 0.45 | 0.79 | 1.05 | 1.13 | 1.49 | 1.89 | 2.36 | 2.86 | 3.37 | |
| Gross profit | — | — | — | — | — | 0.16 | 0.45 | — | 1.04 | 1.12 | 1.47 | 1.85 | 2.32 | 2.81 | — | |
| Research & development | 0.03 | 0.04 | 0.04 | 0.08 | 0.09 | 0.12 | 0.16 | — | — | — | 0.46 | 0.57 | 0.73 | 1.02 | 1.13 | |
| Operating income | 0.03 | 0.00 | -0.05 | -0.09 | -0.15 | -0.13 | 0.04 | 0.07 | 0.16 | 0.10 | 0.25 | 0.25 | 0.57 | 0.62 | 0.79 | |
| Pre-tax income | 0.04 | 0.01 | -0.05 | -0.09 | -0.14 | -0.14 | 0.02 | 0.05 | 0.11 | 0.10 | 0.21 | 0.33 | 0.49 | 0.71 | 0.94 | |
| Income tax | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.30 | 0.01 | 0.06 | 0.08 | 0.14 | 0.23 | 0.23 | |
| Net income | 0.04 | 0.01 | -0.05 | -0.09 | -0.14 | -0.14 | 0.02 | 0.04 | 0.41 | 0.09 | 0.15 | 0.25 | 0.34 | 0.48 | 0.71 | |
| Diluted EPS ($) | 0.67 | 0.08 | -0.69 | -1.05 | -1.63 | -1.62 | 0.22 | 0.39 | 4.16 | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 | 6.82 | |
| Diluted shares (bn) | 0.056 | 0.067 | 0.067 | 0.084 | 0.087 | 0.088 | 0.095 | 0.096 | 0.098 | 0.098 | 0.099 | 0.101 | 0.104 | 0.102 | — |
USD billions · SEC XBRL
Neurocrine Biosciences, Inc. — questions
- What is Neurocrine Biosciences, Inc.'s revenue?
- $3.4B over the twelve months to 2026-06-30, up 34.4% year on year, from its 10-Q and 10-K filings.
- What is Neurocrine Biosciences, Inc.'s net income?
- $705.5M over the twelve months to 2026-06-30.
- What is Neurocrine Biosciences, Inc.'s free cash flow?
- $870.4M over the twelve months to 2026-06-30.
- What are Neurocrine Biosciences, Inc.'s diluted earnings per share?
- $6.82 over the twelve months to 2026-06-30.
Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.